How GLP-1 medicines affect happiness and emotional eating in people with obesity

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a prospective observational study conducted at Erciyes University focusing on adults newly starting GLP-1 receptor agonist therapy for weight management. Participants are assessed at baseline and after 6 months using the Dimensional Anhedonia Rating Scale (DARS) and the Emotional Eating Scale (EES/DYÖ), along with treatment adherence, dose, adverse events, and appetite changes. The goal is to characterize trajectories of anhedonia and emotional eating in relation to GLP-1–driven weight-management therapy in a real-world setting. The study is single-center, enrolling 60 adults, and includes specific eligibility criteria to ensure capacity to complete questionnaires in Turkish. No interventions beyond standard GLP-1 therapy are described.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age 18 years or older
* Newly initiated on GLP-1 receptor agonist treatment for weight reduction
* Willingness to participate in evaluations at baseline and at the 6-month follow-up
* Ability to read and understand Turkish and possess the cognitive capacity to answer questionnaire items
* Voluntary provision of written informed consent

Exclusion Criteria:

* Use of GLP-1 receptor agonists for indications other than weight loss
* Cognitive, neurological, or severe psychiatric conditions preventing completion of self-report questionnaires
* Substantial missing, inconsistent, or unverifiable questionnaire data compromising analysis integrity
* Non-participation or dropout at the 6-month follow-up evaluation

Where it's running

• Erciyes University Medical Faculty Hospitals, Department of Endocrinology and Metabolism
  Kayseri, Melikgazi, Turkey (Türkiye) Recruiting

Study contacts

• Study coordinator: Hasan Durmuş, MD, Assoc. Prof.
• Email: asandurmus@erciyes.edu.tr
• Phone: +90 544 370 6917

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Can tACS modulate motivation and reward signals in cannabis use disorder and depression

  We’re testing whether a gentle brain stimulation method (tACS) can boost motivation and reward responses in adults with cannabis use and/or depression to see if it helps with anhedonia.

  Recruiting Florida State University · Tallahassee, Florida and 1 other locations · NCT07924852

• Ocular Changes in People Using Tirzepatide or Semaglutide

  This study checks whether eye structure and blood vessels change in adults with obesity who are taking semaglutide or tirzepatide as part of routine care.

  Recruiting Istanbul University · Istanbul, Istanbul · NCT07924618

• Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes

  This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.

  Recruiting Pamukkale University · Denizli · NCT07924436

• Berobenatide for knee pain in adults who are overweight or with obesity

  This study tests berobenatide vs. placebo to see if it reduces knee pain and improves function while helping with weight in adults with knee osteoarthritis and overweight/obesity.

  Recruiting at 7 sites Phase 3 Pfizer · Tempe, Arizona and 39 other locations · NCT07919678

• Weekly berobenatide for knee osteoarthritis in adults who are overweight or obese

  This study tests whether weekly berobenatide helps reduce knee pain and improve function, while also affecting body weight, in adults with knee osteoarthritis who are overweight or obese (with or without type 2 diabetes).

  Recruiting Phase 3 Pfizer · Birmingham, Alabama and 3 other locations · NCT07915609

• Maridebart cafraglutide in people who switched from weekly GLP-1 receptor agonists

  This study tests how much maridebart cafraglutide appears in the blood after people with overweight or obesity switch from weekly GLP-1 receptor agonists.

  Recruiting at 9 sites Phase 1 Amgen · Phoenix, Arizona and 8 other locations · NCT07908316

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.